Skip to main content
. 2015 Feb 28;6(10):8388–8396. doi: 10.18632/oncotarget.3460

Figure 2. Overall survival according to the presence ASXL1 mutation in the intermediate cytogenetic patients (A) and according to the presence of TP53 mutation in the unfavorable cytogenetic patients (B).

Figure 2